Jayesh V. Beladiya

Jayesh V. Beladiya

Auto-generated profile, based on publicly available information

Jayesh V. Beladiya

Department of Pharmacology L. M. College of Pharmacy Ahmedabad India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2021 in Biologics
Verified
Journal Article
Open access
PDF file
Vivek P. ChavdaVivek P. Chavda
Vivek P. Chavda
Md Kamal HossainMd Kamal Hossain
Md Kamal Hossain
JBJayesh Beladiya
Jayesh Beladiya
Vasso ApostolopoulosVasso Apostolopoulos
Vasso Apostolopoulos
Coronavirus disease, COVID-19, has touched every country globally except five countries (North Korea, Turkmenistan, Tonga, Tuvalu and Nauru). Vaccination is the most effective method to protect against infectious diseases. The objective is to ensure that everyone has access to a COVID-19 vaccine. The conventional vaccine development platforms are complex and time-consuming to obtain desired approved vaccine candidates through rigorous regulatory pathways. These safeguards guarantee that the optimized vaccine product is safe and efficacious for various demographic populations prior to it being approved for general use. Nucleic acid vaccines employ genetic material from a pathogen, such as a virus or bacteria, to induce an immune response against it. Based on the vaccination, the genetic material might be DNA or RNA; as such, it offers instructions for producing a specific pathogen protein that the immune system will perceive as foreign and mount an immune response. Nucleic acid vaccines for multiple antigens might be made in the same facility, lowering costs even more. Most traditional vaccine regimens do not allow for this. Herein, we demonstrate the recent understanding and advances in nucleic acid vaccines (DNA and mRNA based) against COVID-19, specifically those in human clinical trials.

15 August 2022 in Reviews in Medical Virology
Verified
Journal Article
Closed access
CPChirag Patel
Chirag Patel
KPKrupanshu Parmar
Krupanshu Parmar
DPDipanshi Patel
Dipanshi Patel
SPSandip Patel
Sandip Patel
DSDevang Sheth
Devang Sheth
JBJayesh V. Beladiya
Jayesh V. Beladiya

3 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CPChirag Patel
Chirag Patel
SPSONAL PANDE
SONAL PANDE
VSVrunda Sagathia
Vrunda Sagathia
KETAN M RANCHKETAN M RANCH
KETAN M RANCH
JBJayesh Beladiya
Jayesh Beladiya
MSmoyad shahwan
moyad shahwan
Retinal neurodegeneration is considered an early event in the pathogenesis of several ocular diseases, such as diabetic retinopathy, age-related macular degeneration, and glaucoma. At present, there is no definitive treatment to prevent the progression or reversal of vision loss caused by photoreceptor degeneration and the death of retinal ganglion cells. Neuroprotective approaches are being developed to increase the life expectancy of neurons by maintaining their shape/function and thus prevent the loss of vision and blindness. A successful neuroprotective approach could prolong patients’ vision functioning and quality of life. Conventional pharmaceutical technologies have been investigated for delivering ocular medications; however, the distinctive structural characteristics of the eye and the physiological ocular barriers restrict the efficient delivery of drugs. Recent developments in bio-adhesive in situ gelling systems and nanotechnology-based targeted/sustained drug delivery systems are receiving a lot of attention. This review summarizes the putative mechanism, pharmacokinetics, and mode of administration of neuroprotective drugs used to treat ocular disorders. Additionally, this review focuses on cutting-edge nanocarriers that demonstrated promising results in treating ocular neurodegenerative diseases.

22 July 2019 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
JBJayesh V. Beladiya
Jayesh V. Beladiya
KCKiranj K. Chaudagar
Kiranj K. Chaudagar
AMAnita A. Mehta
Anita A. Mehta

18 December 2023 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
DRDhwani Rana
Dhwani Rana
JBJayesh Beladiya
Jayesh Beladiya
DSDevang Sheth
Devang Sheth
Sagar SalaveSagar Salave
Sagar Salave
ASAmit Sharma
Amit Sharma
DBDerajram Benival
Derajram Benival

31 July 2024 in Reviews in Medical Virology
Verified
Journal Article
Closed access
JBJayesh Beladiya
Jayesh Beladiya
AKAnup Kumar
Anup Kumar
YVYogesh Vasava
Yogesh Vasava
KPKrupanshu Parmar
Krupanshu Parmar
DPDipanshi Patel
Dipanshi Patel
CPChirag Patel
Chirag Patel